In order to minimize the risk of hemodialysis catheter-related bacteremia (CRB), the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines advocate use of tunneled ...

CorMedix sinks 31% in a month after cautious 2026 guidance for DefenCath points to slower adoption and pricing pressure, ...

Vascular Access Device Market OverviewThe global vascular access device market is witnessing consistent growth and is ...

The trust has funded a new state-of-the-art ultrasound machine for Tauranga Hospital’s Kidney Service, significantly ...

CorMedix CRMD has been riding on the success of its lead product, DefenCath (taurolidine plus heparin), which was approved by the FDA in 2023 as the first and only antimicrobial catheter lock solution ...

A new state‑of‑the‑art ultrasound machine is expected to benefit renal patients across Bay of Plenty following a donation from local charitable trust Trinity Lands. The dedicated machine will enhance ...

To register for either the virtual webcast or the in-person event, please click here. CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic ...

CorMedix expects to begin repurchasing shares as early as Q1 2026 and had approximately $150 million in cash and cash equivalents, and 79.3 million common shares outstanding as of December 31, 2025.

Fresenius Medical Care faces ongoing market disinterest, as years of decent free cash flow generation have failed to drive meaningful market returns. Elevated U.S. mortality, a rough flu season, China ...

As we saw in last week’s essay, preventable errors are unnecessary, avoidable threats to obtaining beneficial therapy.Correcting them is prohibitive in terms of financial, emotional and physical ...